Developer docs
API playgroundTry for free, no card

Search company profiles

Bliss Gvs Pharma

Full company profile

uuid003jwix

Namestring
Bliss Gvs Pharma
Legal namestring
Bliss GVS Pharma Ltd
Websiteurl
blissgvs.com
Company typeenum
Public
Founded yearint
1984
Descriptiontext

Bliss GVS Pharma Ltd is an Indian pharmaceutical formulations company founded in 1984 and listed on the NSE (ticker BLISSGVS) and BSE, headquartered in Mumbai with manufacturing operations in Palghar, Maharashtra. The company develops, manufactures, and markets finished dosage forms spanning suppositories, pessaries, capsules, tablets, injectables, and syrups, with a particular focus on niche dosage forms that require specialized manufacturing capabilities not commonly found in commodity generics producers. Its manufacturing facilities are approved under US FDA, EU-GMP, and WHO-GMP regimes, with the Palghar plant's WHO GMP compliance confirmed by a WHO inspection closure report in June 2026.

The company supplies pharmaceutical formulations to regulated markets (US, Europe) and semi-regulated markets (Africa, Asia, Latin America), reaching healthcare providers and end-buyers through established pharmaceutical wholesale and distribution networks. Its revenue model is the sale of pharmaceutical products to distributors and institutional buyers, with pricing not publicly disclosed at the SKU level. Product breadth across multiple dosage forms serves as a hedge against single-product or single-therapeutic-area concentration, though end-customer concentration risk cannot be fully assessed given the absence of named buyer disclosures.

In May–June 2026, Anupam Rasayan India Ltd acquired a controlling 43.3–48.2% equity stake for approximately ₹1,369 crore at ₹299 per share, with a mandatory open offer filed through SBI Capital Markets Ltd for an additional 26% stake scheduled for July 2026; if fully subscribed, Anupam Rasayan would own up to 74.2% of Bliss GVS. The transaction positions Bliss GVS as the vehicle for Anupam Rasayan's entry into finished dosage formulations and signals forthcoming capital deployment for capacity, geographic, or product expansion, while Bliss GVS continues to operate as a standalone listed entity.

Short descriptiontext

Bliss GVS Pharma is an Indian pharmaceutical formulations manufacturer producing niche dosage forms including suppositories, injectables, tablets, capsules, pessaries, and syrups for distribution to regulated and semi-regulated global markets through pharmaceutical wholesale networks.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersAndheri, India
HQ citystring
Andheri
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical formulations, niche dosage forms, generic pharmaceuticals, pharmaceutical manufacturing, finished dosage formulations
Industry2 codes
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIABAD
Oral Solid Dose (OSD) Generics
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceutical Manufacturing
No data
Revenue model1 record
1Pharmaceutical Products Sales
TypeOne Time License
Description

Manufacturing and marketing of pharmaceutical formulations including suppositories, pessaries, injectables, capsules, tablets, and syrups sold to healthcare providers and distributors across regulated and semi-regulated markets

moneycontrol.com
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Bliss GVS Pharma manufactures and markets pharmaceutical formulations in multiple dosage forms, including suppositories, pessaries, injectables, capsules, tablets, and syrups. The company operates WHO-GMP, US FDA, and EU-GMP approved manufacturing facilities, with its Palghar, Maharashtra facility confirmed compliant with WHO GMP standards. Its products are supplied to regulated markets (US, Europe) and semi-regulated markets (Africa, Asia, Latin America) through pharmaceutical distribution networks.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 29.8% YoY revenue growth to ₹257 crore in Q4 FY26
+3 more records
Product overview1 text field

Bliss GVS Pharma is an Indian pharmaceutical formulations company that manufactures and markets a range of dosage forms including suppositories, pessaries, capsules, tablets, injectables, and syrups. The company operates WHO-GMP, US FDA, and EU-GMP-approved manufacturing facilities and supplies to regulated markets in Africa, Asia, Latin America, Europe, and the United States. The product portfolio spans multiple therapeutic areas with a focus on niche dosage forms.

Product and service6 records
1Suppositories
CategoryPharmaceutical Dosage Form
Description

Pharmaceutical suppositories for drug delivery, manufactured at WHO-GMP, US FDA, and EU-GMP approved facilities. Targeted at pharmaceutical distributors and healthcare providers in regulated and semi-regulated markets.

2Pessaries
CategoryPharmaceutical Dosage Form
Description

Pharmaceutical pessaries for gynecological applications, including pelvic organ prolapse and stress urinary incontinence management, manufactured at the company's approved facilities.

3Capsules
CategoryPharmaceutical Dosage Form
Description

Pharmaceutical capsules manufactured at WHO-GMP, US FDA, and EU-GMP approved facilities for distribution in regulated and semi-regulated markets.

4Tablets
CategoryPharmaceutical Dosage Form
Description

Pharmaceutical tablets produced at WHO-GMP, US FDA, and EU-GMP certified manufacturing facilities for global regulated and semi-regulated markets.

5Injectables
CategoryPharmaceutical Dosage Form
Description

Sterile injectable pharmaceutical products manufactured at the company's facilities with international regulatory approvals (US FDA, WHO-GMP, EU-GMP) for global distribution.

6Syrups
CategoryPharmaceutical Dosage Form
Description

Pharmaceutical syrup formulations manufactured and marketed across regulated markets for global distribution through pharmaceutical wholesale networks.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Indian generic pharma with US FDA and WHO-GMP approved plants exporting to regulated and semi-regulated markets. Comparable mid-scale formulations exporter with similar niche/specialty product orientation.

TypeBroad incumbent
Description

Large Indian pharmaceutical company with US FDA, WHO-GMP and EU-GMP approved facilities across formulations, APIs and biologics. Broader portfolio and larger scale than Bliss GVS but overlapping dosage-form and regulatory profile.

TypeDirect peer
Description

Indian pharma with diversified dosage forms including injectables and OSD, exporting to regulated and semi-regulated markets globally. Comparable mid-cap Indian formulations exporter with multi-regulatory approvals.

TypeDirect peer
Description

Indian generic formulations manufacturer with strong presence in Africa, Asia and other emerging markets plus US FDA-approved facilities. Directly comparable to Bliss GVS in geographic mix, regulatory profile, and specialty dosage-form orientation.

TypeDirect peer
Description

Indian pharma with US FDA-approved facilities focused on OSD generics and APIs with active pharmaceutical ingredient integration. Comparable vertically integrated Indian generics platform targeting regulated markets.

TypeDirect peer
Description

Indian generic formulations manufacturer with US FDA-approved facilities serving US and emerging markets. Comparable mid-cap scale and regulatory profile to Bliss GVS.

TypeBroad incumbent
Description

Major Indian pharma with global presence across regulated and emerging markets, including complex generics and specialty dosage forms. Large-scale incumbent operating adjacent product categories and geographies.

TypeDirect peer
Description

Indian pharma with diversified generics portfolio across injectables, OSD and specialty dosage forms serving US, Europe and emerging markets. Comparable multi-dosage-form manufacturer with regulated-market exposure.

TypeBroad incumbent
Description

One of India's largest generic pharma companies with US FDA-approved manufacturing and presence across injectables, OSD and specialty products. Larger scale incumbent overlapping with Bliss GVS in regulated-market generics.

TypeDirect peer
Description

Indian formulations company with US FDA-approved facilities supplying generics to regulated markets, plus API manufacturing. Comparable scale, regulatory profile, and emerging semi-regulated market presence.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bliss Gvs Pharma

Pharmaceutical Manufacturingblissgvs.com

Bliss GVS Pharma is an Indian pharmaceutical formulations manufacturer producing niche dosage forms including suppositories, injectables, tablets, capsules, pessaries, and syrups for distribution to regulated and semi-regulated global markets through pharmaceutical wholesale networks.

What Bliss Gvs Pharma does

Bliss GVS Pharma Ltd is an Indian pharmaceutical formulations company founded in 1984 and listed on the NSE (ticker BLISSGVS) and BSE, headquartered in Mumbai with manufacturing operations in Palghar, Maharashtra. The company develops, manufactures, and markets finished dosage forms spanning suppositories, pessaries, capsules, tablets, injectables, and syrups, with a particular focus on niche dosage forms that require specialized manufacturing capabilities not commonly found in commodity generics producers. Its manufacturing facilities are approved under US FDA, EU-GMP, and WHO-GMP regimes, with the Palghar plant's WHO GMP compliance confirmed by a WHO inspection closure report in June 2026.

The company supplies pharmaceutical formulations to regulated markets (US, Europe) and semi-regulated markets (Africa, Asia, Latin America), reaching healthcare providers and end-buyers through established pharmaceutical wholesale and distribution networks. Its revenue model is the sale of pharmaceutical products to distributors and institutional buyers, with pricing not publicly disclosed at the SKU level. Product breadth across multiple dosage forms serves as a hedge against single-product or single-therapeutic-area concentration, though end-customer concentration risk cannot be fully assessed given the absence of named buyer disclosures.

In May–June 2026, Anupam Rasayan India Ltd acquired a controlling 43.3–48.2% equity stake for approximately ₹1,369 crore at ₹299 per share, with a mandatory open offer filed through SBI Capital Markets Ltd for an additional 26% stake scheduled for July 2026; if fully subscribed, Anupam Rasayan would own up to 74.2% of Bliss GVS. The transaction positions Bliss GVS as the vehicle for Anupam Rasayan's entry into finished dosage formulations and signals forthcoming capital deployment for capacity, geographic, or product expansion, while Bliss GVS continues to operate as a standalone listed entity.

Bliss Gvs Pharma firmographics

Firmographics
Name
Bliss Gvs Pharma
Legal name
Bliss GVS Pharma Ltd
Website
https://blissgvs.com
Company type
Public
Founded year
1984
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Bliss GVS Pharma is an Indian pharmaceutical formulations manufacturer producing niche dosage forms including suppositories, injectables, tablets, capsules, pessaries, and syrups for distribution to regulated and semi-regulated global markets through pharmaceutical wholesale networks.
Ownership category
akta.pro rank

Bliss Gvs Pharma industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIABAD
Oral Solid Dose (OSD) Generics

Keywords

  • Pharmaceutical formulations
  • Niche dosage forms
  • Generic pharmaceuticals
  • Pharmaceutical manufacturing
  • Finished dosage formulations

Where Bliss Gvs Pharma is headquartered

Location

Headquarters

HQ city
Andheri
HQ country
India
HQ region
Asia

Offices2 records

Markets served

Bliss Gvs Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Products Sales: Manufacturing and marketing of pharmaceutical formulations including suppositories, pessaries, injectables, capsules, tablets, and syrups sold to healthcare providers and distributors across regulated and semi-regulated markets

Distribution channels1 record

Bliss Gvs Pharma product offering

Product offering

Core offering

Bliss GVS Pharma manufactures and markets pharmaceutical formulations in multiple dosage forms, including suppositories, pessaries, injectables, capsules, tablets, and syrups. The company operates WHO-GMP, US FDA, and EU-GMP approved manufacturing facilities, with its Palghar, Maharashtra facility confirmed compliant with WHO GMP standards. Its products are supplied to regulated markets (US, Europe) and semi-regulated markets (Africa, Asia, Latin America) through pharmaceutical distribution networks.

Product overview

Bliss GVS Pharma is an Indian pharmaceutical formulations company that manufactures and markets a range of dosage forms including suppositories, pessaries, capsules, tablets, injectables, and syrups. The company operates WHO-GMP, US FDA, and EU-GMP-approved manufacturing facilities and supplies to regulated markets in Africa, Asia, Latin America, Europe, and the United States. The product portfolio spans multiple therapeutic areas with a focus on niche dosage forms.

Differentiator

Problem solved

Functional benefit

Products and services

  • Suppositories Pharmaceutical suppositories for drug delivery, manufactured at WHO-GMP, US FDA, and EU-GMP approved facilities. Targeted at pharmaceutical distributors and healthcare providers in regulated and semi-regulated markets.
  • Pessaries Pharmaceutical pessaries for gynecological applications, including pelvic organ prolapse and stress urinary incontinence management, manufactured at the company's approved facilities.
  • Capsules Pharmaceutical capsules manufactured at WHO-GMP, US FDA, and EU-GMP approved facilities for distribution in regulated and semi-regulated markets.
  • Tablets Pharmaceutical tablets produced at WHO-GMP, US FDA, and EU-GMP certified manufacturing facilities for global regulated and semi-regulated markets.
  • Injectables Sterile injectable pharmaceutical products manufactured at the company's facilities with international regulatory approvals (US FDA, WHO-GMP, EU-GMP) for global distribution.
  • Syrups Pharmaceutical syrup formulations manufactured and marketed across regulated markets for global distribution through pharmaceutical wholesale networks.

Quantifiable outcome

  • 29.8% YoY revenue growth to ₹257 crore in Q4 FY26
  • +3 more outcomes

Companies that use Bliss Gvs Pharma

Customer profile

Segments2 records

Ideal customer profiles2 records

Bliss Gvs Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Bliss Gvs Pharma partnerships and signals

Strategic signal

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Bliss Gvs Pharma competitors and assessment

Company assessment

Direct peers

  • Ipca Laboratories: Indian generic pharma with US FDA and WHO-GMP approved plants exporting to regulated and semi-regulated markets. Comparable mid-scale formulations exporter with similar niche/specialty product orientation.
  • Emcure Pharmaceuticals: Indian pharma with diversified dosage forms including injectables and OSD, exporting to regulated and semi-regulated markets globally. Comparable mid-cap Indian formulations exporter with multi-regulatory approvals.
  • Ajanta Pharma: Indian generic formulations manufacturer with strong presence in Africa, Asia and other emerging markets plus US FDA-approved facilities. Directly comparable to Bliss GVS in geographic mix, regulatory profile, and specialty dosage-form orientation.
  • Granules India: Indian pharma with US FDA-approved facilities focused on OSD generics and APIs with active pharmaceutical ingredient integration. Comparable vertically integrated Indian generics platform targeting regulated markets.
  • Unichem Laboratories: Indian generic formulations manufacturer with US FDA-approved facilities serving US and emerging markets. Comparable mid-cap scale and regulatory profile to Bliss GVS.
  • Glenmark Pharmaceuticals: Indian pharma with diversified generics portfolio across injectables, OSD and specialty dosage forms serving US, Europe and emerging markets. Comparable multi-dosage-form manufacturer with regulated-market exposure.
  • Alembic Pharmaceuticals: Indian formulations company with US FDA-approved facilities supplying generics to regulated markets, plus API manufacturing. Comparable scale, regulatory profile, and emerging semi-regulated market presence.

Broad incumbents

  • Zydus Lifesciences: Large Indian pharmaceutical company with US FDA, WHO-GMP and EU-GMP approved facilities across formulations, APIs and biologics. Broader portfolio and larger scale than Bliss GVS but overlapping dosage-form and regulatory profile.
  • Cipla: Major Indian pharma with global presence across regulated and emerging markets, including complex generics and specialty dosage forms. Large-scale incumbent operating adjacent product categories and geographies.
  • Lupin: One of India's largest generic pharma companies with US FDA-approved manufacturing and presence across injectables, OSD and specialty products. Larger scale incumbent overlapping with Bliss GVS in regulated-market generics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Bliss Gvs Pharma compliance and trust

Trust signal

Compliance3 records

Bliss Gvs Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bliss Gvs Pharma leadership team

Management profile

Number of profiles

Profiles1 record

Bliss Gvs Pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bliss Gvs Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bliss Gvs Pharma

What does Bliss Gvs Pharma do?

Bliss GVS Pharma manufactures and markets pharmaceutical formulations in multiple dosage forms, including suppositories, pessaries, injectables, capsules, tablets, and syrups. The company operates WHO-GMP, US FDA, and EU-GMP approved manufacturing facilities, with its Palghar, Maharashtra facility confirmed compliant with WHO GMP standards. Its products are supplied to regulated markets (US, Europe) and semi-regulated markets (Africa, Asia, Latin America) through pharmaceutical distribution networks.

Is Bliss Gvs Pharma a public or private company?

Bliss Gvs Pharma is a public company. It is classified as public and is currently operating.

When was Bliss Gvs Pharma founded?

Bliss Gvs Pharma was founded in 1984. It employs 1,001 to 5,000 people.

Where is Bliss Gvs Pharma based?

Bliss Gvs Pharma is headquartered in Andheri, India, in the Asia region.

How does Bliss Gvs Pharma make money?

One revenue line is on record: pharmaceutical Products Sales.

Who are Bliss Gvs Pharma's main competitors?

Direct peers on record are Ipca Laboratories, Emcure Pharmaceuticals, Ajanta Pharma, Granules India, Unichem Laboratories, Glenmark Pharmaceuticals and Alembic Pharmaceuticals. Broad incumbents are Zydus Lifesciences, Cipla and Lupin.

Does Bliss Gvs Pharma have an API?

No public API is recorded for Bliss Gvs Pharma.

What industry is Bliss Gvs Pharma in?

Bliss Gvs Pharma's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIABAD, Oral Solid Dose (OSD) Generics. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Financial Express5 Stocks that Delivered Multibagger Returns in 2026Five Indian stocks delivered multibagger returns in 2026, with gains ranging from 296% to 587%. Sterlite Technologies led at 587% on strong fibre demand and a hyperscaler deal, while others like Sigma Advanced Systems and Bliss GVS Pharma rose on ownership changes and order wins. The article notes that such gains can reverse quickly.The Times of IndiaAnupam Rasayan posts strong half-year resultsAnupam Rasayan India reported first-half FY27 revenue of ₹1,489 crore, up 21% year-on-year, and EBITDA of ₹377 crore, up 38%. The company also signed a six-year supply deal with a US speciality metal manufacturer and acquired a controlling stake in Bliss GVS Pharma, signaling diversification into pharmaceuticals.Machine MakerAnupam Rasayan Reports 21% Revenue Growth in H1 FY27 at ₹1,489 CroreAnupam Rasayan reported H1 FY27 revenue of ₹1,489 crore, up 21% year-on-year, with EBITDA rising 38% to ₹377 crore. Q2 FY27 saw record quarterly revenue of ₹821 crore, and the company signed a six-year supply deal with a US metal manufacturer and acquired a 50.07% stake in Bliss GVS Pharma.TradingViewANURAS: H1 growth strengthened margins as Bliss expanded the platform and H2 revenue guidance reached INR 2,400–2,500 croreAnupam Rasayan India Ltd. reported H1 FY27 total income up 21% year-on-year and EBITDA up 38%, with margins improving. Bliss GVS expanded the pharma platform, and the company guided H2 consolidated revenue to INR 2,400–2,500 crore.TradingViewANURAS: H1 revenue rose 21% as Bliss GVS acquisition expanded the platformAnuram's Q2 consolidated total income was ₹821 Cr, with EBITDA of ₹202 Cr and PAT of ₹65 Cr. H1 revenue rose 21% year-over-year to ₹1,489 Cr, and the period included the Bliss GVS acquisition and a six-year US specialty metal supply contract.TradingViewANURAS: Bliss GVS Pharma acquisition reshaped consolidation as H1 revenue reached INR 14,609.15 millionAnurash reported consolidated Q2 revenue of INR 8,059.35 million and PAT of INR 649.69 million, with H1 revenue of INR 14,609.15 million and PAT of INR 1,161.83 million. Bliss GVS Pharma entered consolidation from September 28 with provisional goodwill of INR 10,223.94 million.ScanXBliss GVS subsidiary secures MHRA approval for Mesalazine suppositoriesBliss GVS Pharma's UK subsidiary Asterisk Lifesciences received MHRA marketing authorization for Mesalazine 1g suppositories, enabling UK commercial distribution. The intimation was filed with stock exchanges on November 4, 2026, under SEBI regulations.ScanXAnupam Rasayan posts record FY26 revenue of ₹2,384 croreAnupam Rasayan India Ltd reported record consolidated revenue of ₹2,384 crore for FY26, up 64.6% from ₹1,448 crore in FY25. The company declared a final dividend of ₹1.50 per share and acquired Jayhawk Fine Chemicals and a controlling stake in Bliss GVS Pharma. Management attributed growth to improved capacity utilisation and disciplined working capital.ScanXAnupam Rasayan takes control of Bliss GVS Pharma; promoters reclassifiedAnupam Rasayan India Limited and Mates Visa Consultancy Private Limited acquired control of Bliss GVS Pharma on September 28, 2026, following a share purchase agreement and mandatory open offer. The promoters were reclassified from 'Promoter and Promoter Group' to 'Public' per SEBI regulations, with the updated list filed with stock exchanges.The Times of IndiaAnupam Rasayan expects pharma to contribute one-third of revenue in three yearsAnupam Rasayan expects pharma to contribute one-third of group revenue within three years, leveraging its ₹1,750 crore Bliss GVS Pharma acquisition. Pharma sales have grown from near zero to about ₹300 crore over five years, now 20% of revenue. The company plans to expand US and European contract manufacturing, with Bliss running at 30% capacity.